Macrogen, Inc (038290) Fair Value & Analysis
Healthcare · KR · Market cap 150B KRW
Fair value as of: Jun 24, 2026
Analysis
Macrogen, Inc (038290) currently trades at 11,950 KRW, while our model-based Fair Value estimate is 4,457 KRW — implying the stock looks roughly 62.7% overvalued today. We read business quality at 89/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Macrogen, Inc. provides genetic and genomic analysis research services in South Korea and internationally. It offers next generation sequencing (NGS) services, such as whole genome, exome, targeted, transcriptome, metagenome, epigenome, and single cell multi-omics sequencing, as well as whole genome resequencing; and standard, difficult template, and 16S/18S/26S rRNA and ITS region sequencing services, as well as animal/plant identification, PCR optimization/amplification, pyrosequencing, NGS validation, multi locus sequence typing analysis, sanger sequencing, primer walking, and cloning services. The company also provides fragment analysis services; clinical diagnostic; personal genome analysis; genetic testing services for research purposes, such as messenger RNA, microRNA, single nucleotide polymorphism, comparative genome hybridization, and DNA methylation; oligo and gene synthesis; and clustered regularly interspaced short palindromic repeats design and synthesis material, gRNA…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Macrogen, Inc (038290) undervalued?
What is the fair value of 038290?
What is the quality score of 038290?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.